Nuformix Plc(LSE) NFX

Market Cap£3.37M

Since IPO (2017)-97%

5 Year-91%

1 Year+48%

1 Month-19%

£0.00

+7.69%

+0.00Today

Nuformix Plc last closing stock price
Metric	Price	Date
Last close	GBX 0.14	2026-08-13

Nuformix Plc stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+6.2%	GBX 0.13	2026-08-06
1 month	-19.41%	GBX 0.17	2026-07-14
3 month	-19.41%	GBX 0.17	2026-05-15
Year to date	-46.27%	GBX 0.26	2025-12-31
1 year	+48.11%	GBX 0.09	2025-08-13
3 year	-54.33%	GBX 0.30	2023-08-14
5 year	-91.16%	GBX 1.55	2021-08-13
Since inception	-96.5%	GBX 0.04	2017-10-16

Nuformix Plc Financials at a Glance

Market Cap

£3.37M

Revenue (TTM)

£0.00

Net Income (TTM)

-£4.64M

EPS (TTM)

-£0.00

P/E Ratio

-4.30

Dividend

£0.00

Beta (Volatility)

0.11 (Low)

Dividend

£0.00

Beta (Volatility)

0.11 (Low)

Price

£0.00

Volume

2,258,534

Open

£0.00

Price

£0.00

Volume

2,258,534

Open

£0.00

Previous Close

£0.00

Daily Range

£0.00 - £0.00

52-Week Range

£0.00 - £0.01

Estimated Earnings Date

Dec 2, 2026

Dividend

£0.00

Beta (Volatility)

0.11 (Low)

Price

£0.00

Volume

2,258,534

Open

£0.00

Previous Close

£0.00

Daily Range

£0.00 - £0.00

52-Week Range

£0.00 - £0.01

Estimated Earnings Date

Dec 2, 2026

NFX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nuformix Plc

Nuformix plc is a UK-based pharmaceutical company focused on developing innovative therapies for fibrotic diseases and cancer through drug repurposing. The company is advancing several promising candidates in its portfolio, including NXP001, NXP004, and NXP002.

Products and Services

NXP001: Advanced beyond Phase 1 trials for oncology supportive care
NXP004: A novel variant of Olaparib in intellectual property generation
NXP002: Pre-clinical evaluation for idiopathic pulmonary fibrosis treatment

Growth Outlook

Strong focus on drug repurposing to expedite development timelines
Potential market expansion with NXP001's oncology applications
Innovative pipeline may attract strategic partnerships and funding

Financial Highlights

Recent quarterly net income of -£346,577, reflecting ongoing investment in R&D
TTM price-to-earnings ratio of 4.92 indicates potential undervaluation
Current ratio of 4.32 suggests strong liquidity position

Nuformix plc operates in the biotechnology sector, leveraging its expertise to address significant unmet medical needs. The company's innovative approach to drug repurposing not only aims to reduce development costs but also to bring effective treatments to market more rapidly. With a focus on fibrotic diseases and cancer, Nuformix is positioned to make a meaningful impact in the healthcare landscape. The financial metrics indicate a company in the early stages of growth, with a strong liquidity position and a potentially undervalued stock. As the company progresses through its development pipeline, it may attract further interest from investors and partners alike.

AI Generated • Jul 31, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Anne Brindley, PhD

Website

www.nuformix.com

Headquarters

London, GL EC3V 0HR, GB

NFX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-83.53%

Return on Capital

-87.50%

Return on Assets

-53.59%

Earnings Yield

-23.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£3.37M

Shares Outstanding

2.61B

Volume

2.26M

Avg. Volume

20.34M

Financials (TTM)

Gross Profit

-£49.29K

Operating Income

-£4.65M

EBITDA

-£1.46M

Operating Cash Flow

-£951.02K

Capital Expenditure

£0.00

Free Cash Flow

-£951.02K

Cash & ST Invst.

£930.28K

Total Debt

£0.00

Nuformix Plc Performance Analysis

Nuformix Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-03-31	GBP 0	N/A
2023	2023-09-30	GBP 0	N/A
2024	2024-09-30	GBP 0	N/A
2025	2025-09-30	GBP 0	N/A

Nuformix Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-09-30	N/A
Q2	2025-03-31	N/A
Q4	2025-09-30	N/A
Q2	2026-03-31	N/A

Nuformix Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-03-31	GBP -0.00	-38.9%
2023	2023-09-30	GBP -0.00	-38.9%
2024	2024-09-30	GBP -0.00	275.0%
2025	2025-09-30	GBP -0.00	-91.1%

Nuformix Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-09-30	N/A
Q2	2025-03-31	N/A
Q4	2025-09-30	N/A
Q2	2026-03-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

£0.00

N/A

Gross Profit

£0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

£3.37M

N/A

Market Cap/Employee

£1.12M

N/A

Employees

N/A

Net Income

-£346.58K

-142801.3%

EBITDA

-£332.26K

-141879.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

£930.28K

+406.9%

Total Debt

£0.00

N/A

Accounts Receivable

£50.58K

-48.6%

Inventory

£0.00

N/A

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

-53.59%

N/A

Return on Invested Capital

-61.52%

N/A

Free Cash Flow

-£395.35K

-234428.9%

Operating Cash Flow

-£395.35K

-234427.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OBD.LOxford BioDynamics Plc

OBD.LOxford BioDynamics Plc£0.00+3.85%

TCF.LTheracryf Plc

TCF.LTheracryf Plc£0.00-1.54%

TRX.LTissue Regenix Group plc

TRX.LTissue Regenix Group plc£0.07+0.00%

FUM.LFutura Medical plc

FUM.LFutura Medical plc£0.00-6.83%

IXI.LIXICO plc

IXI.LIXICO plc£0.08+1.33%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$9.77+0.00%

NOKNokia

NOKNokia$10.32+0.09%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$146.15+0.10%

SMCISuper Micro Computer

SMCISuper Micro Computer$37.61+0.19%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x ETF

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x ETF$28.53+0.10%

INTCIntel

INTCIntel$100.95+0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$74.60+0.02%

Questions About NFX

What is the current price of Nuformix Plc?

Nuformix Plc is trading at £0.00 per share.

What is the 52-week range for Nuformix Plc?

Over the past 52 weeks, Nuformix Plc has traded between £0.00 and £0.01.

How much debt does Nuformix Plc have?

As of the most recent reporting period, Nuformix Plc reported total debt of £0.00.

How much cash does Nuformix Plc have on hand?

Nuformix Plc reported £97.55K in cash and cash equivalents in its most recent financial results.

What is Nuformix Plc’s dividend yield?

Nuformix Plc does not currently have a dividend yield.

Nuformix Plc(LSE) NFX

Nuformix Plc Financials at a Glance

NFX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Nuformix Plc

NFX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Nuformix Plc Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NFX

What is the current price of Nuformix Plc?

What is the 52-week range for Nuformix Plc?

How much debt does Nuformix Plc have?

How much cash does Nuformix Plc have on hand?

What is Nuformix Plc’s dividend yield?

Premium Investing Services